تصفح حسب المؤلف "Rizzo, Manfredi"
-
Effect of Bariatric Surgery on Intima Media Thickness: A Systematic Review and Meta-Analysis
Jamialahmadi, Tannaz; Reiner, Željko; Alidadi, Mona; Almahmeed, Wael; Kesharwani, Prashant; Al-Rasadi, Khalid; Eid, Ali H.; Rizzo, Manfredi; Sahebkar, Amirhossein... more authors ... less authors ( Multidisciplinary Digital Publishing Institute (MDPI) , 2022 , Article)Background: Obesity, and in particular extreme obesity, as a global health problem is an important risk factor for many diseases, including atherosclerotic cardiovascular disease (ACVD). Bariatric surgery might stop or ... -
The Effects of Statin Treatment on Serum Ferritin Levels: A Systematic Review and Meta-Analysis
Jamialahmadi, Tannaz; Abbasifard, Mitra; Reiner, Željko; Rizzo, Manfredi; Eid, Ali H.; Sahebkar, Amirhossein... more authors ... less authors ( Multidisciplinary Digital Publishing Institute (MDPI) , 2022 , Article)Background: Statins are the most widely used drugs for decreasing elevated serum LDL-cholesterol (LDL-C) and thus for the prevention of atherosclerotic cardiovascular disease (ASCVD), but they have also some pleiotropic ... -
Effects of Trehalose Administration in Patients with Mucopolysaccharidosis Type III.
Mobini, Moein; Radbakhsh, Shabnam; Kubaski, Francyne; Eshraghi, Peyman; Vakili, Saba; Vakili, Rahim; Abbasifard, Mitra; Jamialahmadi, Tannaz; Rajabi, Omid; Emami, Seyed Ahmad; Tayarani-Najaran, Zahra; Rizzo, Manfredi; Eid, Ali H; Banach, Maciej; Sahebkar, Amirhossein... more authors ... less authors ( Europe PMC , 2023 , Article)Mucopolysaccharidosis type III (MPS III) is a rare autosomal recessive lysosomal storage disease (LSD) caused by a deficiency of lysosomal enzymes required for the catabolism of glycosaminoglycans (GAGs), mainly in the ... -
Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus
Dimitrios, Patoulias; Eid, Ali H.; Rizzo, Manfredi ( Elsevier , 2023 , Article)In a recently published, post-hoc analysis of the hallmark EMPA-REG OUTCOME trial, Kramer ¨ et al.1 assessed whether changes in cardiac and haemodynamic markers achieved with empagliflozin in subjects with type 2 diabetes ...